FDA
-
-
-
-
-
-
-
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
-
-
-
-
-
-
-
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
-
-
-
-
-
-
-
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
-
-
-
-
-
-
-
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
-
-
-
-
-
-
-
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
-
-
-
-
-
-
-
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
-
-
-
-
-
-
-
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

